ArticlePharmaceuticals (Basel, Switzerland)2021

Ten-Year Outcomes of Intravitreal Bevacizumab for Myopic Choroidal Neovascularization: Analysis of Prognostic Factors.

Fabiana Mallone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.